← All trials
NCT01788020
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 1, 2013
- Primary completion
- Dec 1, 2017
- Completion date
- Dec 1, 2022
- First posted
- —
- Last posted
- —
- Enrollment
- 380
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- University of UlmLead sponsor
- Portuguese Institute of OncologyOverall official - principal investigator
- University of AthensOverall official - principal investigator
- University of UlmStudy director
- University of KielStudy chair
- University of UlmReponsible party - principal investigator
- Centre Hospitalier Schaffner FranceOverall official - principal investigator
- University of LeedsOverall official - principal investigator
- University of AmsterdamOverall official - principal investigator
- Karolinska InstituteOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.